KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $273.5 million.

  • GoodRx Holdings' Cash & Equivalents fell 3545.45% to $273.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.5 million, marking a year-over-year decrease of 3545.45%. This contributed to the annual value of $448.3 million for FY2024, which is 3331.12% down from last year.
  • According to the latest figures from Q3 2025, GoodRx Holdings' Cash & Equivalents is $273.5 million, which was down 3545.45% from $281.3 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Cash & Equivalents high stood at $990.5 million for Q1 2021, and its period low was $273.5 million during Q3 2025.
  • For the 5-year period, GoodRx Holdings' Cash & Equivalents averaged around $661.9 million, with its median value being $730.5 million (2022).
  • In the last 5 years, GoodRx Holdings' Cash & Equivalents soared by 93348.71% in 2021 and then crashed by 4668.83% in 2024.
  • Quarter analysis of 5 years shows GoodRx Holdings' Cash & Equivalents stood at $941.1 million in 2021, then decreased by 19.55% to $757.2 million in 2022, then fell by 11.21% to $672.3 million in 2023, then plummeted by 33.31% to $448.3 million in 2024, then crashed by 38.99% to $273.5 million in 2025.
  • Its last three reported values are $273.5 million in Q3 2025, $281.3 million for Q2 2025, and $301.0 million during Q1 2025.